Colorectal Neoplasms
Conditions
Keywords
proteomics, serum peptides, colorectal cancer, MALDI-TOF MS
Brief summary
No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.
Detailed description
Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.
Interventions
OTHERSerum proteomics
magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
Sponsors
Fudan University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
Patients with colorectal cancer Inclusion criteria * histologically confirmed colorectal cancer * aged 18 years or older * have provided written informed consent
Exclusion criteria
* refusal to participate Healthy controls Inclusion criteria * no cancer history * aged 18 years or older * have provided written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum peptide mass fingerprinting (PMF) | 2010.03-2012.05 (2 years) | Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Expressed peptide peaks | 2010.03-2012.05 (2 years) | Find differentially expressed peptide peaks from the model and identify some ideal serum biomarkers for the early diagnosis of colorectal cancer |
Countries
China
Outcome results
None listed